Brown University

Rhode Island Hospital

John M Sedivy

Marco De Cecco

Gerwald Jogl

Alexandra D'ordine

Qian Chen

Walter Kolch

Kam Chi Yeung

Yun Gao

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one LINE 1 (L-1) endonuclease inhibitor. The age-associated inflammation is associated with an upregulation of L1, an accumulation of cytoplasmic L1 cDNA, an activation of an IFN-I response, and/or a reinforcement of a SASP pro-inflammatory state. The L1 EN inhibitor is administered in an amount sufficient to prevent or reverse at least one of the upregulation L1, the accumulation of cytoplasmic L1 cDNA, the activation of the IFN-I response, and/or the SASP pro-inflammatory state.

Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Disclosed are methods for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one long interspersed nuclear element 1 (LINE-1, L1) endonuclease inhibitor (L1 EN inhibitor), either alone or in combination with at least one additional therapeutic agent. Effectiveness of the methods can be measured via biomarkers and/or by a decrease in symptoms compared to those symptoms before administration of the L1 EN inhibitor. Specific chemical structures of the L1 EN inhibitors are identified and shown herein.

Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one reverse transcriptase inhibitor (RTI).

Compositions and methods for treating, preventing or reversing age associated inflammation and disorders

Described herein is are compositions and methods for treating an articulating joint disorders, comprising systemically administering to a subject a nucleoside reverse transcriptase inhibitor (NRTI).

Composition and methods for treating articulating joint disorders with nucleoside reverse transcriptase inhibitors

The invention relates to the discovery of a novel amino acid sequence motif, herein termed the RKIP motif, and to the family of proteins defined by the presence of that motif. Proteins comprising the RKIP motif modulate kinases involved in signal transduction pathways. The RKIP motif forms the basis for screening assays for the identification of agents useful for modulating signal transduction pathways subject to RKIP family mediated regulation, and for the diagnosis and treatment of disorders involving inappropriate activities of pathways subject to RKIP family medicated regulation.

Growing community of inventors

Barrington, RI, United States of America

John M Sedivy